Drug Trial Radar · NCT07596680
CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases
Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Sep 1, 2026
Primary completion
Apr 30, 2028
Study completion Apr 30, 2029
Sponsor
- Lead sponsor
- Nanjing Bioheng Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 19, 2026
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, open-label, investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RD06-05 in patients with autoantibody-mediated autoimmune diseases. The enrolled population consists of patients with active autoimmune diseases, including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), ANCA-associated vasculitis (AAV), idiopathic inflammatory myopathies (IIM), Sjögren's syndrome (SS), among others. The CAR-T cell dose used in this study is 6×10⁶ CAR⁺ T cells/kg. Six subjects will be enrolled for each indication, with a total of 30 subjects to be enrolled.
Conditions
- SLE - Systemic Lupus Erythematosus
- Systemic Sclerosis
- ANCA Associated Vasculitis
- Idiopathic Inflammatory Myopathies
- Sjögren Syndrome
Interventions
RD06-05 CAR-T Cell InjectionDrug
CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
Primary outcomes
What the sponsor says the trial is designed to measure.
- SLE (systemic lupus erythematosus)Time frame: 2 years
- SLE (systemic lupus erythematosus)Time frame: 2 years
- SLE (systemic lupus erythematosus)Time frame: 2 years
- SLE (systemic lupus erythematosus)Time frame: 2 years
- SLE (systemic lupus erythematosus)Time frame: 2 years
- SLE (systemic lupus erythematosus)Time frame: 2 years
- AAV (ANCA-associated vasculitis)Time frame: 2 years
- AAV (ANCA-associated vasculitis)Time frame: 2 years
- IIM (idiopathic inflammatory myopathies)Time frame: 2 years
- SSc (systemic sclerosis)Time frame: 2 years
- SSc (systemic sclerosis)Time frame: 2 years
- SSc (systemic sclerosis)Time frame: 2 years
- SS (Sjögren's syndrome )Time frame: 2 years
- SS (Sjögren's syndrome )Time frame: 2 years
- SS (Sjögren's syndrome )Time frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.